Beacon Therapeutics raises $170 million in a Series B financing
Syncona Ltd announced that it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon...
Syncona to sell Clade Therapeutics to Century Therapeutics for $45 million
LONDON: Syncona Ltd has signed an agreement for the sale of its portfolio company Clade Therapeutics to Century Therapeutics for $45 million. Century is a...
Syncona Ltd to acquire all shares of Freeline Therapeutics at the rate of $6.5/share
LONDON, UK: Syncona Ltd’s newly established portfolio company has entered into an agreement with Freeline Therapeutics Holdings plc to acquire all of the shares of...
Martin Murphy to step down as Chair of Syncona Investment Management Limited
LONDON, UK: Syncona Ltd announced that Martin Murphy is stepping down as Chair of Syncona Investment Management Limited (SIML) with Chris Hollowood taking on the...
Kemal Malik appointed non-executive director at Syncona Ltd
LONDON: Syncona Ltd, a leading healthcare company, announces the appointment of Dr Kemal Malik as a Non-Executive Director with immediate effect. Kemal has 30 years...